evidoria

← Back to browse

Good practice Imported

Yeda Research and Development — Weizmann Institute's Technology-Transfer Company (Rehovot)

Israel · Rehovot · See the Israel profile · See the Rehovot profile

Evidence: Observational / pre–post Top 42% 71/100 · Ask Evidence Copilot about this practice

Since 1959, the Weizmann Institute's wholly owned commercialisation arm has turned basic research into drugs like Copaxone and Erbitux, earning the Institute $50–100m a year in royalties by 2013 and driving $23bn in global sales by 2022.

50-100 USD million
Estimated annual pharmaceutical royalty income (by 2013)
23 USD billion
Cumulative global sales of Institute-originated products (by 2022)
2 USD billion (over NIS 1 billion)
Cumulative royalty income over a six-year period
120 companies
Startup companies founded on Weizmann research (through 2024)
40 %
Share of royalty income returned to inventing scientists
Yeda Research and Development — Weizmann Institute's Technology-Transfer Company (Rehovot) Yeda Research and Development — Weizmann Institute's Technology-Transfer Company (Rehovot)

Details

Maturity
Established
Promoter
Yeda Research and Development Company Ltd. (wholly owned by the Weizmann Institute of Science)
Period
1959–present
Keywords
Technology transfer, patent licensing, life-sciences/biotech commercialisation

Context

Yeda Research and Development Company Ltd. is the wholly owned commercialisation arm the Weizmann Institute of Science set up in 1959 to hold and license the intellectual property generated by its own researchers.

Activities

Yeda files and manages patents on Institute inventions, negotiates licensing and royalty agreements with pharmaceutical and technology partners, returns roughly 40% of royalty income to the inventing scientists, and reinvests the remainder into the Institute's research budget.

Results

The company's largest success is glatiramer acetate, licensed to Teva as Copaxone for multiple sclerosis, alongside Rebif, an NDS satellite-encryption system and Erbitux; these licences drove estimated annual royalties of $50-100 million by 2013, more than $23 billion in cumulative global product sales by 2022, and roughly 120 spin-off startups founded on Institute research through 2024.

Conclusions

Yeda illustrates how a small number of blockbuster licences in a narrow research field can fund a large share of an institute's non-grant income for decades, but the model's dependence on a handful of concentrated wins, and Copaxone's declining revenue since going off-patent in the mid-2010s, means such windfalls are not easily repeated or guaranteed to recur.

Implementation
Indicative cost
Low (< €50k)
Time to results
Long (> 3 years)
Staffing & skills
Yeda Research and Development Company Ltd. staff handle patent filing, licensing negotiation and royalty administration on behalf of Weizmann Institute of Science researchers, operating as a wholly owned subsidiary of the Institute.

Conditions for success

  • The Institute retains full ownership of the intellectual property it generates rather than ceding it to industry partners.
  • Roughly 40% of royalty income is shared directly with inventing scientists, sustaining researcher buy-in.
  • A dedicated pre-commercialisation research unit (BINA, established 2021) supports promising inventions before licensing.

Common failure modes

  • The great majority of income has historically come from a small handful of blockbuster drugs rather than a broad, evenly distributed patent portfolio.
  • Copaxone revenue declined substantially after the drug went off-patent in the mid-2010s, showing concentrated technology-transfer windfalls are not easily repeated.

Commonly funded by

National / regional programmes

Indicative funding routes for practices of this type — always check each programme's current calls and eligibility rules.

Do you run this practice? Claim it — verified implementers get a public contact pathway and can propose corrections.

Data sources

Where this practice's information was retrieved from, and when.

Attachments

Similar practices you may find useful